Investing
Valo’s flagship product is its Opal Computational Platform, designed to create a new model for drug discovery.
The Nashville-based company partners with health plans to offer their members a range of renal care services.
The company plans to use the new money to grow out its business and sales team.
Also: Phil scores $100 million for its prescription refill platform and Synchron rakes in $40 million.
The health startup provides telemedicine services for insurance companies, corporations and government entities.
The deal is expected to close in the second half of 2021 and be worth roughly $4.2 billion.
With this raise, in addition to Nayya’s Series A round from earlier this year, the company has raised nearly $50 million to date.
Frost & Sullivan says the recent shift in attention away from primarily focusing on reproductive-age issues to untapped market areas will be a key factor to the sector’s growth.
The investment will support the development of Ada's symptom assessment and care navigation platform.
The company plans to use the new funds to expand its therapeutics beyond ADHD.